nodes	percent_of_prediction	percent_of_DWPC	metapath
Methsuximide—Glutethimide—CYP11A1—uterine cancer	0.0373	1	CrCbGaD
Methsuximide—Aggression—Progesterone—uterine cancer	0.0306	0.0337	CcSEcCtD
Methsuximide—Proteinuria—Medroxyprogesterone Acetate—uterine cancer	0.0277	0.0306	CcSEcCtD
Methsuximide—Protein urine present—Medroxyprogesterone Acetate—uterine cancer	0.0273	0.0301	CcSEcCtD
Methsuximide—Irritability—Progesterone—uterine cancer	0.0186	0.0205	CcSEcCtD
Methsuximide—Psychotic disorder—Medroxyprogesterone Acetate—uterine cancer	0.0172	0.019	CcSEcCtD
Methsuximide—Irritability—Medroxyprogesterone Acetate—uterine cancer	0.0169	0.0186	CcSEcCtD
Methsuximide—Ataxia—Medroxyprogesterone Acetate—uterine cancer	0.0166	0.0183	CcSEcCtD
Methsuximide—Weight decreased—Progesterone—uterine cancer	0.0152	0.0168	CcSEcCtD
Methsuximide—Drowsiness—Progesterone—uterine cancer	0.015	0.0166	CcSEcCtD
Methsuximide—Weight decreased—Medroxyprogesterone Acetate—uterine cancer	0.0138	0.0152	CcSEcCtD
Methsuximide—Drowsiness—Medroxyprogesterone Acetate—uterine cancer	0.0136	0.015	CcSEcCtD
Methsuximide—Erythema multiforme—Progesterone—uterine cancer	0.0127	0.0141	CcSEcCtD
Methsuximide—Erythema multiforme—Medroxyprogesterone Acetate—uterine cancer	0.0115	0.0128	CcSEcCtD
Methsuximide—Tension—Progesterone—uterine cancer	0.0115	0.0127	CcSEcCtD
Methsuximide—Nervousness—Progesterone—uterine cancer	0.0114	0.0126	CcSEcCtD
Methsuximide—Pancytopenia—Dactinomycin—uterine cancer	0.0113	0.0125	CcSEcCtD
Methsuximide—Vision blurred—Progesterone—uterine cancer	0.0111	0.0122	CcSEcCtD
Methsuximide—Stevens-Johnson syndrome—Dactinomycin—uterine cancer	0.0105	0.0116	CcSEcCtD
Methsuximide—Tension—Medroxyprogesterone Acetate—uterine cancer	0.0104	0.0115	CcSEcCtD
Methsuximide—Nervousness—Medroxyprogesterone Acetate—uterine cancer	0.0103	0.0114	CcSEcCtD
Methsuximide—Confusional state—Progesterone—uterine cancer	0.00966	0.0107	CcSEcCtD
Methsuximide—Anorexia—Progesterone—uterine cancer	0.00913	0.0101	CcSEcCtD
Methsuximide—CACNA1G—decidua—uterine cancer	0.00904	0.189	CbGeAlD
Methsuximide—Erythema multiforme—Dactinomycin—uterine cancer	0.00901	0.00995	CcSEcCtD
Methsuximide—Confusional state—Medroxyprogesterone Acetate—uterine cancer	0.00875	0.00966	CcSEcCtD
Methsuximide—Insomnia—Progesterone—uterine cancer	0.00866	0.00957	CcSEcCtD
Methsuximide—Somnolence—Progesterone—uterine cancer	0.00851	0.0094	CcSEcCtD
Methsuximide—Decreased appetite—Progesterone—uterine cancer	0.00833	0.00919	CcSEcCtD
Methsuximide—Anorexia—Medroxyprogesterone Acetate—uterine cancer	0.00827	0.00914	CcSEcCtD
Methsuximide—Gastrointestinal disorder—Progesterone—uterine cancer	0.00827	0.00913	CcSEcCtD
Methsuximide—Constipation—Progesterone—uterine cancer	0.00819	0.00904	CcSEcCtD
Methsuximide—Pancytopenia—Etoposide—uterine cancer	0.00818	0.00904	CcSEcCtD
Methsuximide—CACNA1H—myometrium—uterine cancer	0.00798	0.167	CbGeAlD
Methsuximide—Feeling abnormal—Progesterone—uterine cancer	0.00789	0.00872	CcSEcCtD
Methsuximide—Insomnia—Medroxyprogesterone Acetate—uterine cancer	0.00785	0.00867	CcSEcCtD
Methsuximide—Gastrointestinal pain—Progesterone—uterine cancer	0.00783	0.00865	CcSEcCtD
Methsuximide—Somnolence—Medroxyprogesterone Acetate—uterine cancer	0.00772	0.00852	CcSEcCtD
Methsuximide—Hiccups—Epirubicin—uterine cancer	0.0077	0.0085	CcSEcCtD
Methsuximide—Stevens-Johnson syndrome—Etoposide—uterine cancer	0.00762	0.00841	CcSEcCtD
Methsuximide—Urticaria—Progesterone—uterine cancer	0.00761	0.0084	CcSEcCtD
Methsuximide—Abdominal pain—Progesterone—uterine cancer	0.00757	0.00836	CcSEcCtD
Methsuximide—Decreased appetite—Medroxyprogesterone Acetate—uterine cancer	0.00754	0.00833	CcSEcCtD
Methsuximide—Gastrointestinal disorder—Medroxyprogesterone Acetate—uterine cancer	0.00749	0.00827	CcSEcCtD
Methsuximide—Leukopenia—Dactinomycin—uterine cancer	0.00742	0.0082	CcSEcCtD
Methsuximide—Constipation—Medroxyprogesterone Acetate—uterine cancer	0.00742	0.0082	CcSEcCtD
Methsuximide—Feeling abnormal—Medroxyprogesterone Acetate—uterine cancer	0.00715	0.0079	CcSEcCtD
Methsuximide—Hiccups—Doxorubicin—uterine cancer	0.00712	0.00787	CcSEcCtD
Methsuximide—Gastrointestinal pain—Medroxyprogesterone Acetate—uterine cancer	0.0071	0.00784	CcSEcCtD
Methsuximide—Urticaria—Medroxyprogesterone Acetate—uterine cancer	0.00689	0.00761	CcSEcCtD
Methsuximide—Abdominal pain—Medroxyprogesterone Acetate—uterine cancer	0.00686	0.00758	CcSEcCtD
Methsuximide—Diarrhoea—Progesterone—uterine cancer	0.00655	0.00724	CcSEcCtD
Methsuximide—Erythema multiforme—Etoposide—uterine cancer	0.00652	0.0072	CcSEcCtD
Methsuximide—Anorexia—Dactinomycin—uterine cancer	0.00645	0.00713	CcSEcCtD
Methsuximide—Dizziness—Progesterone—uterine cancer	0.00633	0.00699	CcSEcCtD
Methsuximide—Vomiting—Progesterone—uterine cancer	0.00609	0.00672	CcSEcCtD
Methsuximide—CACNA1I—lymph node—uterine cancer	0.00607	0.127	CbGeAlD
Methsuximide—Rash—Progesterone—uterine cancer	0.00604	0.00667	CcSEcCtD
Methsuximide—CACNA1H—smooth muscle tissue—uterine cancer	0.00603	0.126	CbGeAlD
Methsuximide—Dermatitis—Progesterone—uterine cancer	0.00603	0.00666	CcSEcCtD
Methsuximide—Headache—Progesterone—uterine cancer	0.006	0.00663	CcSEcCtD
Methsuximide—Diarrhoea—Medroxyprogesterone Acetate—uterine cancer	0.00594	0.00656	CcSEcCtD
Methsuximide—Decreased appetite—Dactinomycin—uterine cancer	0.00588	0.0065	CcSEcCtD
Methsuximide—Dizziness—Medroxyprogesterone Acetate—uterine cancer	0.00574	0.00634	CcSEcCtD
Methsuximide—Nausea—Progesterone—uterine cancer	0.00569	0.00628	CcSEcCtD
Methsuximide—Feeling abnormal—Dactinomycin—uterine cancer	0.00558	0.00616	CcSEcCtD
Methsuximide—Gastrointestinal pain—Dactinomycin—uterine cancer	0.00554	0.00611	CcSEcCtD
Methsuximide—Vomiting—Medroxyprogesterone Acetate—uterine cancer	0.00552	0.00609	CcSEcCtD
Methsuximide—Rash—Medroxyprogesterone Acetate—uterine cancer	0.00547	0.00604	CcSEcCtD
Methsuximide—Dermatitis—Medroxyprogesterone Acetate—uterine cancer	0.00547	0.00604	CcSEcCtD
Methsuximide—Headache—Medroxyprogesterone Acetate—uterine cancer	0.00544	0.006	CcSEcCtD
Methsuximide—Leukopenia—Etoposide—uterine cancer	0.00537	0.00593	CcSEcCtD
Methsuximide—Abdominal pain—Dactinomycin—uterine cancer	0.00535	0.00591	CcSEcCtD
Methsuximide—Ataxia—Epirubicin—uterine cancer	0.00525	0.0058	CcSEcCtD
Methsuximide—CACNA1H—uterus—uterine cancer	0.00517	0.108	CbGeAlD
Methsuximide—Nausea—Medroxyprogesterone Acetate—uterine cancer	0.00515	0.00569	CcSEcCtD
Methsuximide—Confusional state—Etoposide—uterine cancer	0.00494	0.00546	CcSEcCtD
Methsuximide—Ataxia—Doxorubicin—uterine cancer	0.00486	0.00537	CcSEcCtD
Methsuximide—Eosinophilia—Epirubicin—uterine cancer	0.00478	0.00528	CcSEcCtD
Methsuximide—Anorexia—Etoposide—uterine cancer	0.00467	0.00516	CcSEcCtD
Methsuximide—CACNA1H—female reproductive system—uterine cancer	0.00465	0.0971	CbGeAlD
Methsuximide—Diarrhoea—Dactinomycin—uterine cancer	0.00463	0.00511	CcSEcCtD
Methsuximide—Pancytopenia—Epirubicin—uterine cancer	0.00459	0.00506	CcSEcCtD
Methsuximide—Eosinophilia—Doxorubicin—uterine cancer	0.00442	0.00489	CcSEcCtD
Methsuximide—Weight decreased—Epirubicin—uterine cancer	0.00437	0.00482	CcSEcCtD
Methsuximide—Somnolence—Etoposide—uterine cancer	0.00436	0.00481	CcSEcCtD
Methsuximide—Drowsiness—Epirubicin—uterine cancer	0.00431	0.00476	CcSEcCtD
Methsuximide—Vomiting—Dactinomycin—uterine cancer	0.0043	0.00475	CcSEcCtD
Methsuximide—Stevens-Johnson syndrome—Epirubicin—uterine cancer	0.00427	0.00471	CcSEcCtD
Methsuximide—Rash—Dactinomycin—uterine cancer	0.00427	0.00471	CcSEcCtD
Methsuximide—Decreased appetite—Etoposide—uterine cancer	0.00426	0.0047	CcSEcCtD
Methsuximide—Pancytopenia—Doxorubicin—uterine cancer	0.00424	0.00469	CcSEcCtD
Methsuximide—CACNA1H—female gonad—uterine cancer	0.00423	0.0884	CbGeAlD
Methsuximide—Gastrointestinal disorder—Etoposide—uterine cancer	0.00423	0.00467	CcSEcCtD
Methsuximide—Constipation—Etoposide—uterine cancer	0.00419	0.00463	CcSEcCtD
Methsuximide—Haematuria—Epirubicin—uterine cancer	0.00411	0.00453	CcSEcCtD
Methsuximide—Weight decreased—Doxorubicin—uterine cancer	0.00404	0.00446	CcSEcCtD
Methsuximide—Feeling abnormal—Etoposide—uterine cancer	0.00404	0.00446	CcSEcCtD
Methsuximide—Nausea—Dactinomycin—uterine cancer	0.00402	0.00444	CcSEcCtD
Methsuximide—Gastrointestinal pain—Etoposide—uterine cancer	0.00401	0.00442	CcSEcCtD
Methsuximide—Drowsiness—Doxorubicin—uterine cancer	0.00398	0.0044	CcSEcCtD
Methsuximide—Stevens-Johnson syndrome—Doxorubicin—uterine cancer	0.00395	0.00436	CcSEcCtD
Methsuximide—Urticaria—Etoposide—uterine cancer	0.00389	0.0043	CcSEcCtD
Methsuximide—Abdominal pain—Etoposide—uterine cancer	0.00387	0.00428	CcSEcCtD
Methsuximide—Haematuria—Doxorubicin—uterine cancer	0.0038	0.0042	CcSEcCtD
Methsuximide—Erythema multiforme—Epirubicin—uterine cancer	0.00365	0.00404	CcSEcCtD
Methsuximide—Erythema multiforme—Doxorubicin—uterine cancer	0.00338	0.00373	CcSEcCtD
Methsuximide—Diarrhoea—Etoposide—uterine cancer	0.00335	0.0037	CcSEcCtD
Methsuximide—Tension—Epirubicin—uterine cancer	0.0033	0.00365	CcSEcCtD
Methsuximide—Nervousness—Epirubicin—uterine cancer	0.00327	0.00361	CcSEcCtD
Methsuximide—Dizziness—Etoposide—uterine cancer	0.00324	0.00358	CcSEcCtD
Methsuximide—Vision blurred—Epirubicin—uterine cancer	0.00317	0.0035	CcSEcCtD
Methsuximide—Vomiting—Etoposide—uterine cancer	0.00311	0.00344	CcSEcCtD
Methsuximide—Rash—Etoposide—uterine cancer	0.00309	0.00341	CcSEcCtD
Methsuximide—Dermatitis—Etoposide—uterine cancer	0.00309	0.00341	CcSEcCtD
Methsuximide—Headache—Etoposide—uterine cancer	0.00307	0.00339	CcSEcCtD
Methsuximide—Tension—Doxorubicin—uterine cancer	0.00306	0.00337	CcSEcCtD
Methsuximide—Nervousness—Doxorubicin—uterine cancer	0.00302	0.00334	CcSEcCtD
Methsuximide—Leukopenia—Epirubicin—uterine cancer	0.00301	0.00333	CcSEcCtD
Methsuximide—Vision blurred—Doxorubicin—uterine cancer	0.00293	0.00324	CcSEcCtD
Methsuximide—Nausea—Etoposide—uterine cancer	0.00291	0.00321	CcSEcCtD
Methsuximide—Leukopenia—Doxorubicin—uterine cancer	0.00279	0.00308	CcSEcCtD
Methsuximide—Confusional state—Epirubicin—uterine cancer	0.00277	0.00306	CcSEcCtD
Methsuximide—CACNA1H—lymph node—uterine cancer	0.00272	0.0568	CbGeAlD
Methsuximide—Anorexia—Epirubicin—uterine cancer	0.00262	0.00289	CcSEcCtD
Methsuximide—Confusional state—Doxorubicin—uterine cancer	0.00256	0.00283	CcSEcCtD
Methsuximide—Insomnia—Epirubicin—uterine cancer	0.00248	0.00274	CcSEcCtD
Methsuximide—Somnolence—Epirubicin—uterine cancer	0.00244	0.0027	CcSEcCtD
Methsuximide—Anorexia—Doxorubicin—uterine cancer	0.00242	0.00267	CcSEcCtD
Methsuximide—Decreased appetite—Epirubicin—uterine cancer	0.00239	0.00264	CcSEcCtD
Methsuximide—Gastrointestinal disorder—Epirubicin—uterine cancer	0.00237	0.00262	CcSEcCtD
Methsuximide—Constipation—Epirubicin—uterine cancer	0.00235	0.00259	CcSEcCtD
Methsuximide—Insomnia—Doxorubicin—uterine cancer	0.0023	0.00254	CcSEcCtD
Methsuximide—Feeling abnormal—Epirubicin—uterine cancer	0.00226	0.0025	CcSEcCtD
Methsuximide—Somnolence—Doxorubicin—uterine cancer	0.00226	0.00249	CcSEcCtD
Methsuximide—Gastrointestinal pain—Epirubicin—uterine cancer	0.00225	0.00248	CcSEcCtD
Methsuximide—Decreased appetite—Doxorubicin—uterine cancer	0.00221	0.00244	CcSEcCtD
Methsuximide—Gastrointestinal disorder—Doxorubicin—uterine cancer	0.00219	0.00242	CcSEcCtD
Methsuximide—Urticaria—Epirubicin—uterine cancer	0.00218	0.00241	CcSEcCtD
Methsuximide—Constipation—Doxorubicin—uterine cancer	0.00217	0.0024	CcSEcCtD
Methsuximide—Abdominal pain—Epirubicin—uterine cancer	0.00217	0.0024	CcSEcCtD
Methsuximide—Feeling abnormal—Doxorubicin—uterine cancer	0.00209	0.00231	CcSEcCtD
Methsuximide—Gastrointestinal pain—Doxorubicin—uterine cancer	0.00208	0.00229	CcSEcCtD
Methsuximide—Urticaria—Doxorubicin—uterine cancer	0.00202	0.00223	CcSEcCtD
Methsuximide—Abdominal pain—Doxorubicin—uterine cancer	0.00201	0.00222	CcSEcCtD
Methsuximide—CYP2C19—vagina—uterine cancer	0.002	0.0418	CbGeAlD
Methsuximide—Diarrhoea—Epirubicin—uterine cancer	0.00188	0.00208	CcSEcCtD
Methsuximide—Dizziness—Epirubicin—uterine cancer	0.00182	0.00201	CcSEcCtD
Methsuximide—Vomiting—Epirubicin—uterine cancer	0.00175	0.00193	CcSEcCtD
Methsuximide—Diarrhoea—Doxorubicin—uterine cancer	0.00174	0.00192	CcSEcCtD
Methsuximide—Rash—Epirubicin—uterine cancer	0.00173	0.00191	CcSEcCtD
Methsuximide—Dermatitis—Epirubicin—uterine cancer	0.00173	0.00191	CcSEcCtD
Methsuximide—Headache—Epirubicin—uterine cancer	0.00172	0.0019	CcSEcCtD
Methsuximide—Dizziness—Doxorubicin—uterine cancer	0.00168	0.00186	CcSEcCtD
Methsuximide—Nausea—Epirubicin—uterine cancer	0.00163	0.0018	CcSEcCtD
Methsuximide—Vomiting—Doxorubicin—uterine cancer	0.00162	0.00178	CcSEcCtD
Methsuximide—Rash—Doxorubicin—uterine cancer	0.0016	0.00177	CcSEcCtD
Methsuximide—Dermatitis—Doxorubicin—uterine cancer	0.0016	0.00177	CcSEcCtD
Methsuximide—Headache—Doxorubicin—uterine cancer	0.00159	0.00176	CcSEcCtD
Methsuximide—Nausea—Doxorubicin—uterine cancer	0.00151	0.00167	CcSEcCtD
Methsuximide—CACNA1H—Corticotropin-releasing hormone—STAR—uterine cancer	0.000606	0.0655	CbGpPWpGaD
Methsuximide—CACNA1I—Axon guidance—PLXNA3—uterine cancer	0.000481	0.052	CbGpPWpGaD
Methsuximide—CACNA1G—Regulation of nuclear beta catenin signaling and target gene transcription—YWHAE—uterine cancer	0.000368	0.0397	CbGpPWpGaD
Methsuximide—CACNA1H—Corticotropin-releasing hormone—CYP11A1—uterine cancer	0.000363	0.0392	CbGpPWpGaD
Methsuximide—CACNA1G—Axon guidance—PLXNA3—uterine cancer	0.000355	0.0383	CbGpPWpGaD
Methsuximide—CACNA1H—Axon guidance—PLXNA3—uterine cancer	0.000343	0.0371	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—PLXNA3—uterine cancer	0.000343	0.0371	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—PLXNA3—uterine cancer	0.000253	0.0273	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—PLXNA3—uterine cancer	0.000245	0.0265	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—HNF1B—uterine cancer	0.00018	0.0195	CbGpPWpGaD
Methsuximide—CACNA1G—Regulation of nuclear beta catenin signaling and target gene transcription—CDH1—uterine cancer	0.000179	0.0193	CbGpPWpGaD
Methsuximide—CACNA1I—NCAM signaling for neurite out-growth—NRAS—uterine cancer	0.000177	0.0192	CbGpPWpGaD
Methsuximide—CACNA1G—Regulation of nuclear beta catenin signaling and target gene transcription—CDKN2A—uterine cancer	0.000158	0.0171	CbGpPWpGaD
Methsuximide—CACNA1I—NCAM signaling for neurite out-growth—KRAS—uterine cancer	0.000153	0.0165	CbGpPWpGaD
Methsuximide—CACNA1G—Regulation of nuclear beta catenin signaling and target gene transcription—CXCL8—uterine cancer	0.000143	0.0155	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—HNF1B—uterine cancer	0.000133	0.0144	CbGpPWpGaD
Methsuximide—CACNA1G—Regulation of nuclear beta catenin signaling and target gene transcription—CTNNB1—uterine cancer	0.000132	0.0143	CbGpPWpGaD
Methsuximide—CACNA1G—NCAM signaling for neurite out-growth—NRAS—uterine cancer	0.000131	0.0141	CbGpPWpGaD
Methsuximide—CACNA1I—NCAM signaling for neurite out-growth—HRAS—uterine cancer	0.00013	0.014	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—HNF1B—uterine cancer	0.000129	0.0139	CbGpPWpGaD
Methsuximide—CACNA1H—NCAM signaling for neurite out-growth—NRAS—uterine cancer	0.000127	0.0137	CbGpPWpGaD
Methsuximide—CACNA1H—Corticotropin-releasing hormone—CXCL8—uterine cancer	0.000124	0.0134	CbGpPWpGaD
Methsuximide—CACNA1G—Regulation of nuclear beta catenin signaling and target gene transcription—EP300—uterine cancer	0.000123	0.0133	CbGpPWpGaD
Methsuximide—CYP2C19—Arachidonic acid metabolism—AKR1C3—uterine cancer	0.000116	0.0125	CbGpPWpGaD
Methsuximide—CACNA1H—Corticotropin-releasing hormone—CTNNB1—uterine cancer	0.000114	0.0124	CbGpPWpGaD
Methsuximide—CACNA1G—NCAM signaling for neurite out-growth—KRAS—uterine cancer	0.000113	0.0122	CbGpPWpGaD
Methsuximide—CACNA1H—NCAM signaling for neurite out-growth—KRAS—uterine cancer	0.000109	0.0118	CbGpPWpGaD
Methsuximide—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP11A1—uterine cancer	0.000106	0.0114	CbGpPWpGaD
Methsuximide—CYP2C19—Oxidation by Cytochrome P450—CYP11A1—uterine cancer	0.000104	0.0113	CbGpPWpGaD
Methsuximide—CACNA1G—NCAM signaling for neurite out-growth—HRAS—uterine cancer	9.57e-05	0.0103	CbGpPWpGaD
Methsuximide—CACNA1H—NCAM signaling for neurite out-growth—HRAS—uterine cancer	9.27e-05	0.01	CbGpPWpGaD
Methsuximide—CACNA1I—Axon guidance—MET—uterine cancer	9.15e-05	0.00989	CbGpPWpGaD
Methsuximide—CYP2C19—Phase 1 - Functionalization of compounds—CYP11A1—uterine cancer	8.57e-05	0.00926	CbGpPWpGaD
Methsuximide—CYP2C19—Metapathway biotransformation—AKR1B10—uterine cancer	8.07e-05	0.00872	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—SMAD3—uterine cancer	7.97e-05	0.00861	CbGpPWpGaD
Methsuximide—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP19A1—uterine cancer	7.78e-05	0.0084	CbGpPWpGaD
Methsuximide—CYP2C19—Oxidation by Cytochrome P450—CYP19A1—uterine cancer	7.68e-05	0.00829	CbGpPWpGaD
Methsuximide—CYP2C19—Metapathway biotransformation—AKR1B1—uterine cancer	7.5e-05	0.00811	CbGpPWpGaD
Methsuximide—CACNA1G—Axon guidance—MET—uterine cancer	6.75e-05	0.00729	CbGpPWpGaD
Methsuximide—CACNA1I—Axon guidance—ERBB2—uterine cancer	6.69e-05	0.00723	CbGpPWpGaD
Methsuximide—CACNA1H—Axon guidance—MET—uterine cancer	6.53e-05	0.00706	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—MET—uterine cancer	6.53e-05	0.00706	CbGpPWpGaD
Methsuximide—CACNA1H—Corticotropin-releasing hormone—AKT1—uterine cancer	6.43e-05	0.00694	CbGpPWpGaD
Methsuximide—CYP2C19—Phase 1 - Functionalization of compounds—CYP19A1—uterine cancer	6.31e-05	0.00681	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—SMAD3—uterine cancer	5.88e-05	0.00635	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—SMAD3—uterine cancer	5.69e-05	0.00615	CbGpPWpGaD
Methsuximide—CYP2C19—Metapathway biotransformation—AKR1C1—uterine cancer	5.51e-05	0.00595	CbGpPWpGaD
Methsuximide—CACNA1I—Axon guidance—VEGFA—uterine cancer	5.15e-05	0.00557	CbGpPWpGaD
Methsuximide—CACNA1I—Axon guidance—NRAS—uterine cancer	5.09e-05	0.0055	CbGpPWpGaD
Methsuximide—CACNA1G—Axon guidance—ERBB2—uterine cancer	4.93e-05	0.00533	CbGpPWpGaD
Methsuximide—CYP2C19—Metapathway biotransformation—GPX3—uterine cancer	4.84e-05	0.00522	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—MET—uterine cancer	4.81e-05	0.0052	CbGpPWpGaD
Methsuximide—CACNA1H—Axon guidance—ERBB2—uterine cancer	4.78e-05	0.00516	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—ERBB2—uterine cancer	4.77e-05	0.00516	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—MET—uterine cancer	4.66e-05	0.00504	CbGpPWpGaD
Methsuximide—CYP2C19—Biological oxidations—CYP11A1—uterine cancer	4.55e-05	0.00492	CbGpPWpGaD
Methsuximide—CYP2C19—Metapathway biotransformation—CYP11A1—uterine cancer	4.49e-05	0.00485	CbGpPWpGaD
Methsuximide—CACNA1I—Axon guidance—KRAS—uterine cancer	4.38e-05	0.00473	CbGpPWpGaD
Methsuximide—CYP2C19—Metapathway biotransformation—AKR1C3—uterine cancer	4.24e-05	0.00458	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—CTNNB1—uterine cancer	4.18e-05	0.00451	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—SRD5A2—uterine cancer	4.04e-05	0.00437	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—EP300—uterine cancer	3.88e-05	0.00419	CbGpPWpGaD
Methsuximide—CACNA1G—Axon guidance—VEGFA—uterine cancer	3.8e-05	0.0041	CbGpPWpGaD
Methsuximide—CACNA1G—Axon guidance—NRAS—uterine cancer	3.75e-05	0.00405	CbGpPWpGaD
Methsuximide—CACNA1I—Axon guidance—HRAS—uterine cancer	3.72e-05	0.00402	CbGpPWpGaD
Methsuximide—CACNA1H—Axon guidance—VEGFA—uterine cancer	3.68e-05	0.00397	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—VEGFA—uterine cancer	3.68e-05	0.00397	CbGpPWpGaD
Methsuximide—CACNA1H—Axon guidance—NRAS—uterine cancer	3.63e-05	0.00393	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—NRAS—uterine cancer	3.63e-05	0.00392	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—ERBB2—uterine cancer	3.52e-05	0.0038	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—ERBB2—uterine cancer	3.41e-05	0.00368	CbGpPWpGaD
Methsuximide—CYP2C19—Biological oxidations—CYP19A1—uterine cancer	3.35e-05	0.00362	CbGpPWpGaD
Methsuximide—CYP2C19—Metapathway biotransformation—CYP19A1—uterine cancer	3.3e-05	0.00357	CbGpPWpGaD
Methsuximide—CACNA1G—Axon guidance—KRAS—uterine cancer	3.23e-05	0.00349	CbGpPWpGaD
Methsuximide—CACNA1H—Axon guidance—KRAS—uterine cancer	3.13e-05	0.00338	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—KRAS—uterine cancer	3.13e-05	0.00338	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—CTNNB1—uterine cancer	3.08e-05	0.00333	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—CTNNB1—uterine cancer	2.98e-05	0.00322	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—STAR—uterine cancer	2.92e-05	0.00316	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—AKR1B1—uterine cancer	2.92e-05	0.00316	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—EP300—uterine cancer	2.86e-05	0.00309	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—EP300—uterine cancer	2.77e-05	0.00299	CbGpPWpGaD
Methsuximide—CACNA1G—Axon guidance—HRAS—uterine cancer	2.74e-05	0.00297	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—VEGFA—uterine cancer	2.71e-05	0.00293	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—NRAS—uterine cancer	2.68e-05	0.00289	CbGpPWpGaD
Methsuximide—CACNA1H—Axon guidance—HRAS—uterine cancer	2.66e-05	0.00287	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—HRAS—uterine cancer	2.66e-05	0.00287	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—VEGFA—uterine cancer	2.63e-05	0.00284	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—NRAS—uterine cancer	2.59e-05	0.0028	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—AKT1—uterine cancer	2.35e-05	0.00253	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—KRAS—uterine cancer	2.3e-05	0.00249	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—KRAS—uterine cancer	2.23e-05	0.00241	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	2.14e-05	0.00232	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—HRAS—uterine cancer	1.96e-05	0.00212	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—HRAS—uterine cancer	1.9e-05	0.00205	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—NDUFB11—uterine cancer	1.8e-05	0.00194	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—SRD5A2—uterine cancer	1.8e-05	0.00194	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	1.75e-05	0.00189	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—AKT1—uterine cancer	1.73e-05	0.00187	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—AKT1—uterine cancer	1.68e-05	0.00181	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	1.65e-05	0.00178	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—AKR1B1—uterine cancer	1.3e-05	0.00141	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—STAR—uterine cancer	1.3e-05	0.00141	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	1.29e-05	0.00139	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—POLD1—uterine cancer	1.02e-05	0.0011	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—AKR1C1—uterine cancer	9.55e-06	0.00103	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—RRM2—uterine cancer	8.51e-06	0.00092	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—DCN—uterine cancer	8.26e-06	0.000893	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—CYP11A1—uterine cancer	7.79e-06	0.000841	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—AKR1C3—uterine cancer	7.35e-06	0.000794	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—CYP19A1—uterine cancer	5.73e-06	0.000619	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—STK11—uterine cancer	5.73e-06	0.000619	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	5.38e-06	0.000581	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—EP300—uterine cancer	5.13e-06	0.000554	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—MTHFR—uterine cancer	4.3e-06	0.000465	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	3.79e-06	0.00041	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—PTEN—uterine cancer	2.39e-06	0.000259	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—EP300—uterine cancer	2.28e-06	0.000247	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—PIK3CA—uterine cancer	1.69e-06	0.000183	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—AKT1—uterine cancer	1.38e-06	0.000149	CbGpPWpGaD
